Technical Articles

Based on the clinical treatment challenges of multiple myeloma (MM), this article systematically elaborates on the limitations of existing therapies and the urgent need for novel immunotherapies. It analyzes the successful experience of CD19 CAR-T in B-cell malignancies and its challenges in MM due to target expression barriers. The molecular characteristics and expression advantages of BCMA as a MM plasma cell-specific surface antigen are discussed, providing a theoretical foundation for its suitability as a CAR-T therapy target.